Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 5/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | TNK2 | Q07912 | 5/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | DCK | P27707 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30739402 | 0.89 | MAP4K4 (0.37) | MAP4K4PDE4BPDE4DTNK2TRPA1 | |
| SCHEMBL30739323 | 0.88 | MAP4K4 (0.36) | MAP4K4PDE4BPDE4DTNK2TRPA1 | |
| SCHEMBL30739376 | 0.83 | BRD4 (0.40) | — | |
| SCHEMBL30739393 | 0.80 | MAP4K4 (0.32) | MAP4K4L3MBTL1PIK3CD | |
| SCHEMBL30739427 | 0.77 | BRD4 (0.42) | — | |
| SCHEMBL30739237 | 0.77 | BLK (0.39) | MAP4K4 | |
| SCHEMBL30739280 | 0.76 | KMT2A (0.39) | L3MBTL1 | |
| SCHEMBL30739145 | 0.75 | TEK (0.37) | MAP4K4 | |
| SCHEMBL30739425 | 0.70 | CYP3A4 (0.38) | MAP4K4PDE4BPDE4DTNK2PIK3CD | |
| SCHEMBL30739301 | 0.65 | MAP4K4 (0.42) | MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117466897-A | Highly selective FGFR2 inhibitors | 深圳福沃药业有限公司 | 2024-01-30 | — | — | CN | disclosed |